Immune checkpoint inhibitors have demonstrated clinical activity, with efficacy and significant survival benefit for anti-programmed cell death protein 1 (PD-1), anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4), or combined immunotherapies in patients with metastatic melanoma and other tumor entities. Here, PDCD1 is linked to neoplasm.